Resiquimod controlled-release - Vaccex
Alternative Names: VX001 - VaccexLatest Information Update: 28 Aug 2023
At a glance
- Originator Vaccex
- Class Adjuvants; Antineoplastics; Antivirals; Imidazoles; Quinolones; Skin disorder therapies; Small molecules
- Mechanism of Action Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Colorectal cancer; Solid tumours
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Breast-cancer in USA (Intratumoural, Controlled release)
- 28 Aug 2023 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (Intratumoural, Controlled release)
- 28 Aug 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (Intratumoural, Controlled release)